Movement Alert｜Moderna Rises 5.14% in Regular Trading, Secures Up to $50 Million CEPI Funding for Ebola Vaccine Development

Market Focus06-05

On June 4, Moderna rose 5.14% in regular trading, trading at $51.77/share, with trading volume of $169 million. The rally was driven by news that Moderna has expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a potential vaccine against the Bundibugyo Ebolavirus.

CEPI has committed up to $50 million in funding to support preclinical development and phase 1 clinical testing of Moderna's vaccine candidate. The funding will also support parallel manufacturing activities during clinical evaluation and position the program for advancement into large-scale phase 2/3 trials, contingent upon favorable phase 1 safety and immunogenicity data. Additionally, the company had previously disclosed it is fully prepared to complete production and supply deployment for its recommended COVID vaccine components by mid-August, reinforcing confidence in its operational execution across multiple pipeline programs.

Moderna is a leader in mRNA medicine, with its platform enabling the development of therapies and vaccines across infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125251079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125251079","market":"us","top_or_hot":-1,"title":"Movement Alert｜Moderna Rises 5.14% in Regular Trading, Secures Up to $50 Million CEPI Funding for Ebola Vaccine Development","media":"Market Focus","content":"<p><p>On June 4, Moderna rose 5.14% in regular trading, trading at $51.77/share, with trading volume of $169 million. The rally was driven by news that Moderna has expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a potential vaccine against the Bundibugyo Ebolavirus.</p><p>CEPI has committed up to $50 million in funding to support preclinical development and phase 1 clinical testing of Moderna's vaccine candidate. The funding will also support parallel manufacturing activities during clinical evaluation and position the program for advancement into large-scale phase 2/3 trials, contingent upon favorable phase 1 safety and immunogenicity data. Additionally, the company had previously disclosed it is fully prepared to complete production and supply deployment for its recommended COVID vaccine components by mid-August, reinforcing confidence in its operational execution across multiple pipeline programs.</p><p>Moderna is a leader in mRNA medicine, with its platform enabling the development of therapies and vaccines across infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna Rises 5.14% in Regular Trading, Secures Up to $50 Million CEPI Funding for Ebola Vaccine Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna Rises 5.14% in Regular Trading, Secures Up to $50 Million CEPI Funding for Ebola Vaccine Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Moderna rose 5.14% in regular trading, trading at $51.77/share, with trading volume of $169 million. The rally was driven by news that Moderna has expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a potential vaccine against the Bundibugyo Ebolavirus.</p><p>CEPI has committed up to $50 million in funding to support preclinical development and phase 1 clinical testing of Moderna's vaccine candidate. The funding will also support parallel manufacturing activities during clinical evaluation and position the program for advancement into large-scale phase 2/3 trials, contingent upon favorable phase 1 safety and immunogenicity data. Additionally, the company had previously disclosed it is fully prepared to complete production and supply deployment for its recommended COVID vaccine components by mid-August, reinforcing confidence in its operational execution across multiple pipeline programs.</p><p>Moderna is a leader in mRNA medicine, with its platform enabling the development of therapies and vaccines across infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1125251079","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125251079","pubTimestamp":1780592230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Moderna rose 5.14% in regular trading, trading at $51.77/share, with trading volume of $169 million. The rally was driven by news that Moderna has expanded its collaboration with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"动向提示|Moderna常规交易涨5.14%获高达5000万美元CEPI资金用于埃博拉疫苗研发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On June 4, Moderna rose 5.14% in regular trading, trading at $51.77/share, with trading volume of $169 million. The rally was driven by news that Moderna has expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a potential vaccine against the Bundibugyo Ebolavirus.CEPI has committed up to $50 million in funding to support preclinical development and phase 1 clinical testing of Moderna's vaccine candidate. The funding will also support parallel manufacturing activities during clinical evaluation and position the program for advancement into large-scale phase 2/3 trials, contingent upon favorable phase 1 safety and immunogenicity data. Additionally, the company had previously disclosed it is fully prepared to complete production and supply deployment for its recommended COVID vaccine components by mid-August, reinforcing confidence in its operational execution across multiple pipeline programs.Moderna is a leader in mRNA medicine, with its platform enabling the development of therapies and vaccines across infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125251079","isCrawlerRequest":true}